Variable | Unadjusted | Adjusted* | ||||
HR | 95% CI | P values | HR | 95% CI | P values | |
Intensive treatment (yes) | 2.473 | 2.074 to 2.949 | <0.0001 | 2.372 | 1.985 to 2.833 | <0.0001 |
Age, years† (6.8 years) | 1.377 | 1.274 to 1.489 | <0.0001 | 1.134 | 1.038 to 1.238 | 0.0054 |
Black race (yes) | 1.746 | 1.465 to 2.080 | <0.0001 | 1.425 | 1.188 to 1.708 | <0.0001 |
Education (less than college) | 1.477 | 1.204 to 1.810 | 0.0002 | 1.314 | 1.070 to 1.614 | 0.0092 |
Time since diabetes diagnosis, years† (7.7) | 1.507 | 1.407 to 1.615 | <0.0001 | 1.125 | 1.037 to 1.220 | 0.0047 |
Hypoglycemia in the last week (yes) | 2.465 | 2.000 to 3.037 | <0.0001 | 1.361 | 1.091 to 1.697 | 0.0063 |
Creatinine† (mmol/L) (0.020) | 1.029 | 1.023 to 1.035 | <0.0001 | 1.124 | 1.041 to 1.214 | 0.0029 |
Urinary albumin creatinine† (381.1) | 1.189 | 1.136 to 1.245 | <0.0001 | 1.129 | 1.069 to 1.192 | <0.0001 |
SBP, mm Hg† (17.7) | 1.196 | 1.108 to 1.292 | <0.0001 | 1.175 | 1.066 to 1.295 | 0.0012 |
DBP, mm Hg† (10.9) | 0.783 | 0.721 to 0.850 | <0.0001 | 0.817 | 0.735 to 0.907 | 0.0002 |
Waist circumference, cm† (13.6) | 0.895 | 0.826 to 0.970 | 0.0071 | 0.876 | 0.806 to 0.952 | 0.0019 |
Insulin use (yes) | 3.222 | 2.732 to 3.800 | <0.0001 | 2.138 | 1.765 to 2.590 | <0.0001 |
Sulfonylurea use (yes) | 0.392 | 0.325 to 0.472 | <0.0001 | 0.684 | 0.561 to 0.834 | 0.0002 |
Biguanide use (yes) | 0.441 | 0.376 to 0.518 | <0.0001 | 0.738 | 0.619 to 0.880 | 0.0007 |
Meglitinide use (yes) | 1.338 | 1.074 to 1.667 | 0.0094 | 1.286 | 1.027 to 1.611 | 0.0285 |
HMG-CoA reductase inhibitors use (yes) | 0.951 | 0.804 to 1.126 | 0.5619 | 0.811 | 0.683 to 0.964 | 0.0172 |
Antihypertensive use (yes) | 2.464 | 1.651 to 3.677 | <0.0001 | 1.899 | 1.263 to 2.856 | 0.0021 |
*Adjusted for all other variables in the risk prediction model.
†HR and 95% CI for 1 SD increment in the continuous variables.
ACCORD, Action to Control Cardiovascular Risk in Diabetes; DBP, diastolic blood pressure; SBP, systolic blood pressure.